CC
APLS

CIBRA Capital’s Apellis Pharmaceuticals APLS Stock Holding History

CIBRA Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.01M Buy
+50,000
New +$1.08M 0.97% 22

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CIBRA Capital's APLS Position: Q1 2026 in Review

CIBRA Capital opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 50,000 shares worth $2.01M. The stake represents 0.97% of the portfolio and ranks #22 among its holdings.

323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • CIBRA Capital held 50,000 shares of Apellis Pharmaceuticals worth $2.01M as of Q1 2026.
  • Apellis Pharmaceuticals was a new CIBRA Capital position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.97% of CIBRA Capital's portfolio in Q1 2026, its #22 holding.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on CIBRA Capital's 13F filing for Q1 2026, filed 24 Apr 2026.